This article was originally published in Pharmaceutical Approvals Monthly
Ramipril receives additional indication Oct. 4 to reduce risk of stroke, myocardial infarction and cardiovascular death. The ACE inhibitor was previously approved for treatment of hypertension and congestive heart failure following myocardial infarction. Altace labeling has been updated to highlight data supporting efficacy in diabetic patients. The diabetic subpopulation of the pivotal study had a 25% reduction in the incidence of cardiovascular events when compared to placeb
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.